The Herceptin Biosimilar Market is carefully analyzed in the report with an emphasis on market dynamics, including key issues and challenges, drivers, trends, and opportunities. The report includes an in-depth analysis of significant market players to understand the utilization of the main strategies that have been adopted in the Herceptin Biosimilar market. It also sheds light on the industrial value chain and its expected changes over the forecast period.
Herceptin is a monoclonal antibody used to treat patients suffering from metastatic (spread) breast cancer and gastric cancers. Hereceptin is used as part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu protein positive breast cancer. Herceptin is also known as trastuzumab and mainly administered intravenously in cancer patients, the dose of herceptin given to patients is evaluated on the basis of patients’ disease history and other physiological factors such as height, weight, type of cancer or disease condition.
Get Full PDF Sample Copy of Report: https://www.coherentmarketinsights.com/insight/request-pdf/4258
Market Dynamics
Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.
Key features of the study:
- This report provides in-depth analysis of the global herceptin biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
Top Major Key Players in the Global Herceptin Biosimilars Market:
Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.
Table of Contents
-
Research Objectives and Assumptions
-
Research Objectives
-
Assumptions
-
Abbreviations
-
-
Market Preview
-
Report Description
-
Market Definition and Scope
-
-
Executive Summary
-
Market Snippet, By Indication
-
Market Snippet, By Distribution Channel
-
Market Snippet, By Region
-
Coherent Opportunity Map (COM)
-
-
-
Market Dynamics, Regulations, and Trends Analysis
-
Market Dynamics
-
Drivers
-
Restraints
-
Impact Analysis
-
-
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
